On November 17, 2026, Isomorphic Labs, an AI company focused on designing and developing new medicines, announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several other new investors, with continued significant investment from Alphabet. The financing also included participation from Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. Wilson Sonsini Goodrich & Rosati advised Isomorphic Labs on the transaction.
Isomorphic is scaling its proprietary drug design engine (IsoDDE) and therapeutic candidate pipeline designed with AI to deliver the next generation of medicines. This new capital accelerates the scientific breakthroughs and proprietary AI advances being made by Isomorphic. The company will continue to mature IsoDDE as well as expand deeper into new biology with highly advanced models.
The Wilson Sonsini team that advised Isomorphic Labs on the transaction includes Andrew Gillman, Betty Rosenbaum, Olivia Cusimano, Adam Enochs, and Victoria Burch.
For more information, please see Isomorphic Labs' news release. Additional coverage can be found on Bloomberg, Fierce Biotech, and TechCrunch.